Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies

Clostridioides difficile infection (CDI) and recurrent CDI (rCDI) remain associated with a reduction in the patients’ quality of life and with increased healthcare costs. Bezlotoxumab is a monoclonal antibody against toxin B of C. difficile, approved for prevention of rCDI. In this narrative review,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Infect Dis Ther
Asıl Yazarlar: Giacobbe, Daniele Roberto, Dettori, Silvia, Di Bella, Stefano, Vena, Antonio, Granata, Guido, Luzzati, Roberto, Petrosillo, Nicola, Bassetti, Matteo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2020
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7452994/
https://ncbi.nlm.nih.gov/pubmed/32632582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-020-00314-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller